Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma
| Autor: | Mina Iwanishi, Toshiharu Sakurai, Naoshi Nishida, Yasunori Minami, Masatoshi Kudo, Norihisa Yada, Satoshi Kitai, Satoru Hagiwara, Kazuomi Ueshima, Tomohiro Minami, Masahiro Takita, Tadaaki Arizumi, Masashi Kono, Masayuki Kitano, Hirokazu Chishina, Tatsuo Inoue, Hiroshi Ida |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Carcinoma Hepatocellular medicine.medical_treatment Antineoplastic Agents Gastroenterology 03 medical and health sciences 0302 clinical medicine Japan Internal medicine medicine Carcinoma Hepatectomy Humans Chemoembolization Therapeutic Stage (cooking) Survival rate Neoplasm Staging Retrospective Studies business.industry Standard treatment Liver Neoplasms Reproducibility of Results Retrospective cohort study General Medicine medicine.disease Survival Rate 030220 oncology & carcinogenesis Hepatocellular carcinoma 030211 gastroenterology & hepatology Liver cancer business Follow-Up Studies |
| Zdroj: | Digestive Diseases. 34:671-678 |
| ISSN: | 1421-9875 0257-2753 |
| Popis: | Background: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child-Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al. [Semin Liver Dis 2012;32:348-359], we developed the Kinki criteria focusing on a substaging for BCLC stage B disease, which is simpler and should be more suitable in actual clinical setting in Japan. In this study, we evaluated the performance of Kinki criteria. Summary: This study included 1,633 HCC patients who received first-line treatment at the Kindai University Hospital. Patients were classified into subgroups based on the Kinki criteria and the survival time was estimated for each group. There were 156 (33.3%) patients in subclass B1, 278 (59.3%) in B2, and 35 (7.4%) in B3. The median overall survival times and 95% CI for BCLC B subclasses B1, B2, and B3 were 4.3 years (3.7-4.9), 2.9 years (2.2-3.4), and 1.1 years (0.5-1.8), respectively (p < 0.001). Key Messages: Classification of HCC patients in BCLC stage B based on the Kinki criteria showed statistically significant differences in survival, indicating the performance of Kinki criteria, which takes Child-Pugh score and tumor status into account for determining treatment options for HCC in BCLC stage B. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|